Volume 30, Issue 9 pp. 776-779
Full Access

Prevalence of anti-HCV in Norwegian blood donors with anti-HBc or increased ALT levels

Geir Hetland MD

Corresponding Author

Geir Hetland MD

Medical Officer

Blood Bank and Department of Immunology, Ullevaal Hospital, 0407 Oslo 4, NorwaySearch for more papers by this author
K. Skaug

K. Skaug

Kjell Skaug, PhD, Head, Section of Immunology of Infectious Diseases, Department of Microbiology, Ullevaal Hospital

Search for more papers by this author
J. Larsen

J. Larsen

John Larsen, MD, Medical Officer, Blood Bank and Deprtment of Immunology

Search for more papers by this author
A. Mæland

A. Mæland

Arild Mæland, MD, Medical Director, Department of Infectious Diseases, Ullevaal Hospital

Search for more papers by this author
J.H. Strømme

J.H. Strømme

Johan H. Strømme, MD, Professor, Department of Clinical Chemistry, Ullevaal Hospital

Search for more papers by this author
G. Størvold

G. Størvold

Gunnar Størvold, MD, Medical Director, Department of Microbiology

Search for more papers by this author
First published: November‐December 1990
Citations: 12

Abstract

Testing for hepatitis B core antibodies (anti-HBc) was performed in 12,104 consecutive blood donors, 139 (1.15%) of whom were found to be positive. The first 6036 donors were also screened for ALT; 91 (1.51%) had repeatedly elevated values. ALT screening was of no help in detecting anti-HBc-positive donors. Those with anti-HBc or repeatedly raised ALT levels were further tested for hepatitis C virus antibodies (anti-HCV), and 3 (2.16%) and 1 (1.10%) anti-HCV-positive donors were detected, respectively. This prevalence of anti-HCV (0.5%) is not significantly different from that found in 1000 unselected donors at our blood bank. Testing for ALT and anti-HBc as surrogate markers for hepatitis C is therefore not recommended in Norwegian blood donors and should be replaced by anti-HCV screening.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.